Efficacy and safety of Benacort (budesonide solution) in therapy of asthma exacerbation
Abstract
The study was designed to search efficiency and safety of the 3-rd generation glucocorticosteroid (GCS) budesonide (Benacort) as 0.05 % nebulized solution in patients with exacerbation of moderate bronchial asthma (BA). The study involved 18 males and 12 females aged 42 to 65 yrs suffering from BA for 3 months to 30 yrs, 27 of them completed the investigation. Three patients broke off the study because of unpleasant taste, sour throat, cough attacks during the inhalations. Before the study 22 patients had not received any basic therapy, 8 ones had been treated with inhaled GSC 600 to 1 200 meg daily or cromones. Starting the study all the patients had moderate exacerbations of BA.
The budesonide solution was inhaled via a nebulizer 1 000 to 2 000 meg daily. All the patients also received inhaled β2-agonists. The efficacy of budesonide was evaluated with clinical picture, lung function parameters, need in β2-agonists. The therapy with nebulized budesonide lasted 7 to 10 days. The full control of BA was reached in 5 (18 % ) of the patients, sufficient control was in 10 (37 % ) and partial control was obtained in 13 (48 % ) of them. There were not significant shifts in endogenous cortisol and glucose levels, arterial blood pres sure and heart beat rate parameters for the treatment period. So, this study demonstrated that the nebulized Benacort is highly effective and safe when used in patients with BA exacerbations. Combined administration of nebulized β2-agonists and GCS is thought to be the alternative for systemic GCS and xanthines.
About the Authors
N. R. Paleev
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
N. K. Chereiskaya
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
R. S. Tishenina
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
T. V. Stotskaya
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
E. F. Dorofeeva
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
V. V. Rakitskaya
МОНИКИ им. М .Ф .Владимирского;
Больница № 2 г. Королев Московской области
Russian Federation
Russian Federation
References
1. Глобальная стратегия лечения и профилактики бронхиальной астмы. Пересмотр 2002 г.: Пер. с англ. М.: Атмосфера; 2002.
2. Чучалин А.Г. Бронхиальная астма. М.: Агар; 1997; т. 2: 151-159.
3. Agertoft L., Andersen A., Weibull Е., Pedersen S. Systemic
4. availability and pharmacokinetics of nebulised budesonide in preschool children. Arch. Dis. Child. 1999; 80 (3): 241-247.
5. Alkiewicz J., Szczawinska-Poplonyk A., Makowska M. [Stability of inhaled drugs as a requisite for safe therapy as for example, with nebulised glucocorticosteroids). Pneumonol. Alergol. Pol. 1997; 65 (suppl. 1): 7-17.
6. Alkiewicz J. [Inhaled glucocorticosteroids-distribution, stability, therapy]. Wiad. Lek. 1998; 51 (suppl. 1): 5-11.
7. Angus R.M. Inhaled corticosteroids (budesonide): the cornerstone of asthma therapy — what are the options? Pulm. Pharmacol. Ther. 2002; 15 (6): 479-484.
8. Cates C.J., Adams N., Bestall J. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst. Rev. 2001; 2: CD001491.
9. Turner M .O ., Patel A., Ginsburg S., FitzGerald J.M. Bronchodilatator delivery in acute airflow obstruction. A metaanalysis. Arch. Intern. Med. 1997; 157: 1736-1744.
10. Dahlstrom K., Thorsson L., Larsson P., Nikander K. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann. Allergy Asthma Immunol. 2003; 90 (2): 226-232.
11. Nikander K., Agertoft L., Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J. Asthma 2000; 37 (5): 451-459.
12. Dempsey O.J., Humphreys М ., Coutie W.J., Lipworth B.J. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. Eur. J. Clin. Pharmacol. 2001; 57 (9): 637-641.
13. Price J., Lenney W., Duncan C. et al. HPA-axis effects of nebu lised fluticasone propionate compared with oral prednisolone in childhood asthma. Respir. Med. 2002; 96 (8): 625-631.
14. Shapiro G., Mendelson L., Kraemer M.J. et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J. Allergy Clin. Immunol. 1998; 102 (5): 789-796.
15. Szefler S.J. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J. Allergy Clin. Immunol. 1999; 104 (4, pt 2): 175-183.
16. Szefler S.J., Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J. Allergy Clin. Immunol. 2002; 109 (4): 730-742.
17. Ferguson A.D., Emerson R.M., English J.S. Cross-reactivity patterns to budesonide. Contact Dermatit. 2002; 47 (6): 337-340.
Review
For citations:
Paleev N.R., Chereiskaya N.K., Tishenina R.S., Stotskaya T.V., Dorofeeva E.F., Rakitskaya V.V. Efficacy and safety of Benacort (budesonide solution) in therapy of asthma exacerbation. PULMONOLOGIYA. 2004;(2):63-67. (In Russ.)
Views:
203
Email this article 